Compare Abeona Therapeutics Inc (ABEO) vs Philip Morris International Inc. (PM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Philip Morris International Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Philip Morris International Inc. trades at $188.28 (market cap $287.96B). The key difference: Philip Morris International Inc. is far larger — about 771.3× Abeona Therapeutics Inc's market cap, and Philip Morris International Inc. pays a 3.18% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PM | |
|---|---|---|
Market Cap | $373.32M | $287.96B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $191.86 |
52-Week Low | $4.17 | $144.33 |
Enterprise Value | $228.22M | $334.46B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Philip Morris International (PM) trades at $184.76, up 1.37% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings beat ($1.96 vs $1.86 expected) and maintains robust profitability with 26.74% net income margin. Recent news includes a $500 million impairment charge on Canadian operations and updated 2026 guidance, though IQOS brand recognition remains a positive catalyst.
PM offers stable revenue growth and strong cash flow generation, but faces headwinds from currency volatility and illicit market pressures. Analyst consensus remains bullish with $194.25 price target (68% buy ratings), though recent profit forecast cuts and high debt levels warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
